

JUL 11 2007

**INFORMATION  
DISCLOSURE  
STATEMENT**

Atty. Docket No.: 180.00120101

Serial No.: 10/591,199

Applicant(s): Zhao Yi Wang

Confirmation No.: 4302

Application Filing Date: August 30, 2006

Group: 1646

Information Disclosure Statement mailed: July 9, 2007

**U.S. PATENT DOCUMENTS**

Examiner Initial	Copy Enclosed	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		4,036,945	07/19/1977	Haber			
		4,331,647	05/25/1982	Goldenberg			
		4,946,778	08/07/1990	Ladner et al.			
		5,053,133	10/01/1991	Klein et al.			
		5,223,409	06/29/1993	Ladner et al.			
		5,403,484	04/04/1995	Ladner et al.			
		5,116,750	05/26/1992	Gelfand et al.			
		5,168,049	12/01/1992	Meade et al.			
		5,560,922	10/01/1996	Chien et al.			
		5,571,698	11/05/1996	Ladner et al.			
		5,595,887	01/21/1997	Coolidge et al.			
		5,788,983	08/04/1998	Chien et al.			
		6,127,150	10/03/2000	Coolidge et al.			
		6,306,434 B1	10/23/2001	Hong et Al.			
		6,342,221 B1	01/29/2002	Thorpe et Al.			
		6,365,146 B1	04/02/2002	Uhrich			
		6,534,281 B2	03/18/2003	Kitajima et Al.			
		6,558,924 B1	05/06/2003	Stahl et Al.			
		6,664,372 B1	12/16/2003	Janda et Al.			
		2004/0180819 A1	09/16/2004	Deecher et Al.			

EXAMINER

Date Considered

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

**Foreign patent documents**

Examiner initial	Copy enclosed	Document number	Date	Country	Class	Subclass	Translati	
							Yes	No
	x	WO 01/00823 A1	01/04/2001	PCT				
	x	WO 01/62969 A2, A3	08/30/2001	PCT				
	x	WO 02/097044 A2, A3	12/05/2002	PCT				
	x	WO 2005/087811 A2, A3	09/22/2005	PCT				

**Other documents (Including Authors, Title, Date, Pertinent Papers, Etc.)**

Examiner initial	Copy enclosed	Document Description
	x	Abbondanza et al., "Characterization and Epitope Mapping of a New Panel of Monoclonal Antibodies to Estrogen Receptor," <i>Steroids</i> , 1993; 58:4-12.
	x	Åkesson "New approaches to pharmacological treatment of osteoporosis," 2003 <i>Bulletin of the World Health Organization</i> 81(9):657-664.
	x	Altucci et al., "17 $\beta$ -Estradiol Induces Cyclin D <sub>1</sub> Gene Transcription, p36 <sup>D</sup> <sub>1</sub> -p34 <sup>cdk4</sup> Complex Activation and p105 <sup>Rb</sup> Phosphorylation During Mitogenic Stimulation of G <sub>1</sub> -arrested Human Breast Cancer Cells," <i>Oncogene</i> , 1996; 12:2315-2324.
	x	Altucci et al., "Estrogen Induces Early and Timed Activation of Cyclin-dependent Kinases 4, 5, and 6 and Increases Cyclin Messenger Ribonucleic Acid Expression in Rat Uterus," <i>Endocrinology</i> , 1997; 138:978-984.
	x	American Type Cell Culture. Accession No. Htb-22. Designation Mcf7. Available Online [Retrieved 2007-05-02]. Retrieved from the Internet: < <a href="http://www.atcc.org/common/catalog/numsearch/numresults.cfm">http://www.atcc.org/common/catalog/numsearch/numresults.cfm</a> >; 4 pgs.
	x	Anderson et al., "BRCA1 Protein Is Linked to the RNA Polymerase II Holoenzyme Complex via Rna Helicase A," <i>Nat Genet.</i> , 1998; 19:254-256.

<b>EXAMINER</b>	<b>Date Considered</b>
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	"Anti-estrogen Receptor/rat Anti-estrogen Receptor (Clone H222)" Datasheet [Online]. Research Diagnostics, Inc., Concord, Ma, Rev. 17 March 2005 [Retrieved on 2006-10-19]. Retrieved from the Internet:<Url:http://www.researchd.com/rdiabs/estorec.htm>; 10 pgs.
	x	Aronica et al., "Estrogen Action via the cAMP Signaling Pathway: Stimulation of Adenylate Cyclase and cAMP-regulated Gene Transcription," <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994; 91:8517-8521.
	x	Bachelier et al., "Effect of Bilateral Oophorectomy on Mammary Tumor Formation in BRCA1 Mutant Mice," <i>Oncol. Rep.</i> , 2005; 14:1117-1120.
	x	Barany and Merrifield (Gross and Meienhofer, Eds.) <i>The Peptides, Analysis, Synthesis, Biology</i> , Volume 2, Academic Press: New York, NY; 1980. Table of Contents, and Chapter 1 Table of Contents, 9 pgs.
	x	Beato et al. "Steroid Hormone Receptors: Many Actors in Search of a Plot." 1995 <i>Cell</i> 83:851-857.
	x	Berry et al., "Role of the Two Activating Domains of the Oestrogen Receptor in the Cell-type and Promoter-context Dependent Agonistic Activity of the Anti-oestrogen 4-hydroxytamoxifen," <i>Embo Journal</i> , 1990; 9:2811-2818.
	x	Bird et al. "Single-chain Antigen-binding Proteins." 1988 <i>Science</i> 242(4877):423-426.
	x	Björnström et al., "Estrogen Receptor-dependent Activation of Ap-1 via Non-genomic Signaling," <i>Nuclear Receptor</i> , 2004; 1-11.
	x	Borgna "Contirbution à l'élucidation du mécanisme d'action antioestrogénique et antitumoral du tamoxifène," 1994 <i>Bull Cancer</i> 81:29-37. <b>English language abstract only.</b>
	x	Boussif et al., "A Versatile Vector for Gene and Oligonucleotide Transfer into Cells in Culture and in Vivo: Polyethylenimine," <i>PNAS</i> , 1995; 92:7297-7301.
	x	Campbell et al., "Phosphatidylinositol 3-kinase/akt-mediated Activation of Estrogen Receptor $\alpha$ : a New Model for Anti-estrogen Resistance," <i>Journal of Biological Chemistry</i> , 2001; 276:9817-9824.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Carlomagno et al., "c-erb-B2 Overexpression Decreases the Benefit of Adjuvant Tamoxifen in Early-stage Breast Cancer Without Axillary Lymph Node Metastases," <i>J. Clin. Oncol.</i> , 1996; 14:2702-2708.
	x	Carell et al., "A Novel Procedure for the Synthesis of Libraries Containing Small Organic Molecules," 1994 <i>Angewandte Chemie International Edition English</i> 33:2059-2061.
	x	Carter et al., "Humanization of an Anti-p185 <sup>HER2</sup> for Human Cancer Therapy," 1992, <i>PNAS</i> ; 89:4285-4289.
	x	Castilla et al., "Mutations in the BRCA1 Gene Families with Early-onset Breast and Ovarian Cancer," <i>Nature Genet.</i> , 1994; 8:387-391.
	x	Castoria et al., "Non-transcriptional Action of Oestradiol and Progesterin Triggers Dna Synthesis," <i>EMBO</i> , 1999; 18:2500-2510.
	x	Cerillo et al., "The Oestrogen Receptor Regulates NfκB and AP-1 Activity in a Cell-specific Manner," <i>J. Steroid Biochem. Mol. Biol.</i> , 1998; 67(2):79-88.
	x	Chen et al., "Rb Associated Protein 46 (RbAp46) Inhibits Transcriptional Transactivation Mediated by BRCA1," <i>Biochem Biophys Res Commun</i> , 2001; 284:507-514.
	x	Chen et al., "The C-Jun N-terminal Kinase Pathway and Apoptotic Signaling," <i>Int. J. Oncol.</i> , 2000; 16:651-662.
	x	Chen et al., "Estrogen Receptor α Mediates the Nongenomic Activation of Endothelial Nitric Oxide Synthase by Estrogen," <i>Journal of Clinical Investigation</i> , 1999; 103:401-406.
	x	Cho et al., "An unnatural biopolymer," <i>Science</i> , 1993; 261(5126):1303-1305.
	x	Clark et al., "Correlations between estrogen receptor, progesterone receptors, and patient characteristics in human breast cancer," <i>J. Clin. Oncol.</i> , 1984; 2:1102-1109.
	x	Clark et al., "Prognostic and predictive factors," <i>Diseases of the Breast</i> , vol. 2, Lippincott Williams & Wilkins, Philadelphia, PA 2000; 38:489-514.
	x	Clark-Lewis et al., "16: Chemical Synthesis, Purification, and Folding of C-X-C and C-C chemokines," 1997 <i>Metho. Enzymol.</i> 287:233

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Clarke et al., "Cellular and molecular pharmacology of antiestrogen action and resistance," <i>Pharmacol. Rev.</i> , 2001; 53:25-71.
	x	Clarke et al., "Dissociation between steroid receptor expression and cell proliferation in the human breast," <i>Cancer Res.</i> , 1997; 57:4987-4991.
	x	Clarke et al., "Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling," <i>Oncogene</i> , 2003; 22:7316-7339.
	x	Coligan et al., "Unit 9" <i>Current Protocols in Immunology</i> , Wiley Interscience, 1991, Volume 3, Table of Contents for Volume 3 and Unit 9, 6 pgs.
	x	Coligan et al. <i>Current Protocols in Immunology</i> , Wiley Interscience, 1995, Volume 1, Table of Contents, publisher's page, and sections 2.4.1, 2.5.1 - 2.6.7, 2.8.1 - 2.8.10 and 2.10.1 - 2.10.4; 1992.
	x	Committee on Methods of Producing Monoclonal Antibodies "Monoclonal Antibody Production" Institute for Laboratory Animal Research, National Research Council: The National Academies Press 1999.
	x	Connor et al., "Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor," <i>Cancer Res.</i> , 2001; 61:2917-2922.
	x	Coopman et al., "Anti-Proliferative and anti-estrogenic affects of ICI 164,384 and ICI 182,780 in 4-OH-Tamoxifen-Resistant human breast-cancer cells," 1994 <i>Int. J. Cancer</i> 56:295-300.
	x	Cull et al., "Screening for Receptor Ligands Using Large Libraries of Peptides Linked to the C Terminus of the lac Repressor," <i>Proc. Natl. Acad. Sci. USA</i> , 1992; 89:1865-1869.
	x	Cwirla et al., "Peptides on Phage: A Vast Library of Peptides for Identifying Ligands," <i>Proc. Natl. Acad. Sci. USA</i> , 1990; 87:6378-6382.
	x	Dang et al., "Peroxisome Proliferator-Activated Receptor $\gamma$ (PPAR $\gamma$ ) as a Molecular Target for the Soy Phytoestrogen Genistein," <i>J. Biol. Chem.</i> , 2003; 278(2):962-967.
	x	Dauvois et al., "Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover," <i>Proc. Natl. Acad. Sci. USA</i> , 1992; 89:4037-4041.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	DeConinck et al., "Transcriptional regulation of estrogen receptor in breast carcinomas," <i>Mol. Cell Biol.</i> , 1995; 15:2191-2196.
	x	Denger et al., "ER $\alpha$ gene expression in human primary osteoblasts: evidence for the expression of two receptor proteins," <i>Molecular Endocrinology</i> , 2001; 15:2064-2077.
	x	DeWitt et al., "'Diversomers': An Approach to Nonpeptide, Nonoligomeric Chemical Diversity," <i>Proc. Natl. Acad. Sci. USA</i> , 1993; 90:6909-6913.
	x	Devlin, "Random peptide libraries: a source of specific protein binding molecules," <i>Science</i> , 1990; 249(4967):404-406.
	x	Diaz-Chico et al., "A 46-kDa antigen associated with estrogen receptor in human breast cancer," <i>J. Steroid Biochem.</i> , 1988; 30:315-320.
	x	Dobrzycka et al., "Estrogen receptor corepressors -- a role in human breast cancer?" <i>Endocrine Related Cancer</i> , 2003; 10(4):517-536.
	x	Dotzlaw et al., "Characterization of estrogen receptor variant mRNAs from human breast cancers," <i>Molecular Endocrinology</i> , 1992; 6:773-85.
	x	Driggers et al., "Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling," <i>Trends in Endocrinology and Metabolism</i> , 2002; 13:422-427.
	x	Eckert et al., "Estrogen receptor synthesis and turnover in MCF7 breast cancer cells measured by a density shift technique," <i>Endocrinology</i> , 1984; 114:629-637.
	x	Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> , 2001; 411:494-498.
	x	Endoh et al., "Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function of human estrogen receptor $\alpha$ ," <i>Mol. Cell Biol.</i> , 1999; 19:5363-5372.
	x	Engelman et al., "Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth," <i>The Journal of Biological Chemistry</i> , 1997; 272:16374-16381.
	x	Engelman et al., "Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer," <i>The Journal of Biological Chemistry</i> , 1998; 273:20448-20455.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Engelman et al., "p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression," <i>The Journal of Biological Chemistry</i> , 1999; 274:32333-32341.
	x	Erb et al., "Recursive Deconvolution of Combinatorial Chemical Libraries," <i>PNAS</i> , 1994; 91:11422.
	x	"ERK Antibodies" datasheet [online]. Santa Cruz Biotechnology, Inc., Santa Cruz, CA, ©2006 Santa Cruz Biotechnology, Inc. [retrieved on 2006-10-17]. Retrieved from the Internet <URL: <a href="http://www.scbt.com/table.php?table=ERK">http://www.scbt.com/table.php?table=ERK</a> > and <a href="http://www.scbt.com/product.php?datasheet=94">http://www.scbt.com/product.php?datasheet=94</a> >; 2 pgs.
	x	Evans et al., "Design of nonpeptidal ligands for a peptide receptor: cholecystinin antagonists," <i>J. Med. Chem.</i> , 1987; 30(7):1229-1239.
	x	Evans et al., "Reciprocal Antagonism Between Estrogen Receptor and NF-κB Activity In Vivo," <i>Circ. Res.</i> , 2001; 89:823-830.
	x	Fan et al., "BRCA1 inhibition of estrogen receptor signaling in transfected cells," <i>Science</i> , 1999; 284:1354-1356.
	x	Fan et al., "Role of direct interaction in BRCA1 inhibition of estrogen receptor activity," <i>Oncogene</i> , 2001; 20:77-87.
	x	Farhat et al., "The vascular protective effects of estrogen," <i>FASEB J.</i> , 1996; 10:615-624.
	x	Fauchere, "Elements for the rational design of peptide drugs," <i>J. Adv. Drug Res.</i> , 1986; 15:29-69.
	x	Fawell et al., "Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization," <i>Proc. Natl. Acad. Sci. USA</i> , 1990; 87:6883-6887.
	x	Feigelson et al., "Estrogens and breast cancer," <i>Carcinogenesis</i> , 1996; 17:2279-2284.
	x	Felici, "Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent expression vector," <i>J. Mol. Biol.</i> , 1991; 222(2):301-310.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Ferguson et al., "Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression," <i>Cancer Res.</i> , 1995; 55:2279-2283.
	x	Figtree et al., "Truncated estrogen receptor $\alpha$ 46-kDa isoforms in human endothelial cells: Relationship to acute activation of nitric oxide synthase," <i>Circulation</i> , 2003; 107:120-126.
	x	Fiucci et al., "Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells," <i>Oncogene</i> , 2002; 21:2365-75.
	x	Flouriot et al., "Identification of a new isoform of the human estrogen receptor- $\alpha$ (hER- $\alpha$ ) that is encoded by distinct transcripts and that is able to repress hER- $\alpha$ activation function 1," <i>EMBO</i> , 2000; 19:4688-4700.
	x	Flouriot et al., "Differentially expressed messenger RNA isoforms of the human estrogen receptor- $\alpha$ gene are generated by alternative splicing and promoter usage," <i>Molecular Endocrinology</i> , 1998; 12:1939-1954.
	x	Fodor, "Multiplex biochemical assays with biological chips," <i>Nature</i> , 1993; 364:555-556.
	x	Foulkes et al., "Estrogen receptor status in BRCA1-and -BRCA2-related breast cancer: The influence of age, grade and histological type," <i>Clin. Cancer Res.</i> , 2004; 10:2029-2034.
	x	Frasor et al. "Profiling Estrogen Up- and Down-Regulated Gene Expression in Human Breast Cancer Cells: Insights into Gene Networks and Pathways Underlying Estrogenic Control of Proliferation and Cell Phenotype." 2003 <i>Endocrinology</i> 144:4562.
	x	Friedman et al., "Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian-cancer in 10 families," <i>Nature Genet.</i> , 1994; 8:399-404.
	x	Futreal et al., "BRCA1 mutations in primary breast and ovarian carcinomas," <i>Science</i> , 1994; 266:120-122.
	x	Galbiati et al., "Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade," <i>EMBO</i> , 1998; 17:6633-6648.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	



<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Gallop et al., "Application of Combinatorial Technologies to Drug Technology. 1. Background and Peptide Combinatorial Libraries," <i>J. Med. Chem.</i> , 1994; 37(9):1233-1251.
	x	Gottardis et al., "Development of tamoxifen stimulated growth of MCF-7 tumors in athymic mice after a long-term antiestrogen administration," <i>Cancer Res.</i> , 1988; 48:5183-5187.
	x	Gram et al. "In Vitro Selection and Affinity Maturation of Antibodies from a Naive Combinatorial Immunoglobulin Library." 1992 PNAS 89:3576-3580.
	x	Green et al., "Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A," <i>Nature</i> , 1986; 320:134-139.
	x	<del>Green (Manson, Ed.) "Production of Polyclonal Antisera" Immunochemical Protocols Humana Press: city, state, 1992 pp:1-5.</del>
	x	Green et al. "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs," 1994 Nat Gen 7:13-21.
	x	Greenberg et al., "Prostate Cancer in a Transgenic Mouse," <i>Proc. Natl. Acad. Sci. USA</i> , 1995; 92:3439-3443.
	x	Greene et al., "Sequence and expression of human estrogen receptor complementary DNA," <i>Science</i> , 1986; 231:1150-1154.
	x	Gruvberger et al., "Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns," 2001 <i>Cancer Research</i> 61:5979-5984.
	x	Gu et al., "Rapid action of 17 $\beta$ -estradiol on kainate-induced currents in hippocampal neurons lacking intracellular estrogen receptors," <i>Endocrinology</i> , 1999; 140:660-666.
	x	Hall et al. "The Multifaceted Mechanisms of Estradiol and Estrogen Receptro Signaling." 2001 J. Biol. Chem. 276(40):36869-36872.
	x	Harlow et al., <i>Antibodies: A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988; table of contents and pp. 319, 726.
	x	Harnish et al. "The Role of CBP in Estrogen Receptor Cross-Talk with Nuclear Factor- $\kappa$ B in HepG2 Cells." <i>Endocrinology</i> , 2000; 141:3403-3411.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Hayashi et al., "Invasion activating caveolin-1 mutation in human scirrhou breast cancers," <i>Cancer Research</i> , 2001; 61:2361-2364.
	x	Hopp et al., "Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates," <i>Clin. Cancer Res.</i> , 2004; 10:2751-2760.
	x	Hosking et al., "A somatic BRCA1 mutation in an ovarian tumor," <i>Nature Genet.</i> , 1995; 9:343-344.
	x	Houghten "The Use of Synthetic Peptide Combinatorial Libraries for the Identification of Bioactive Peptides," <i>Bio Techniques</i> , 1992; 13(3):412-421.
	x	Inbar et al. "Localization of Antibody-Combining Sites within the Variable Portions of Heavy and Light Chains." 1972 PNAS 69:2659
	x	Ishida et al., "RET: a poly A-trap retrovirus vector for reversible disruption and expression monitoring of genes in living cells," <i>Nucleic Acids Res.</i> , 1999; 27:580-591.
	x	Jacque et al., "Modulation of HIV-1 replication by RNA interference," <i>Nature</i> , 2002; 418:435-438.
	x	Jazaeri et al., "Expression of Estrogen Receptor Alpha mRNA and Protein Variants in Human Endometrial Carcinoma," <i>Gynecologic Oncology</i> , 1999; 74(1):38-47.
	x	Jiang et al., "Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor," <i>Journal of the National Cancer Institute</i> , 1992; 84:580-591.
	x	Joel et al., "pp90 <sup>tsk1</sup> regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167," <i>Molecular and Cellular Biology</i> , 1998; 273:13317-13323.
	x	Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <i>Nature</i> , 1986; 321:522-525.
	x	Jozan et al., "65 and 47 kDa forms of estrogen receptor in human breast cancer: relation with estrogen responsiveness," <i>Breast Cancer Research and Treatment</i> , 1991; 19:103-109.
	x	Kametaka et al. "Reduction of CTLL-2 Cytotoxicity by Induction of Apoptosis with a Fas-estrogen Receptor Chimera." 2003 Cancer Sci 94(7):639-643.

**EXAMINER****Date Considered**

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Kay et al., <i>Phage Display of Peptides and Proteins: A Laboratory Manual</i> , Academic Press, San Diego, CA, 1996; Title page and table of contents only.
	x	Karp et al., "Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women," <i>Cancer</i> , 1997; 80:435-441.
	x	Katzenellenbogen et al., "Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta - regulation by selective estrogen receptor modulators and importance in breast cancer," <i>Breast Cancer Res.</i> , 2000; 2:335-344.
	x	Katzenellenbogen et al., "Biomedicine. Defining the 'S' in SERMs," <i>Science</i> , 2002; 295(5564):2380-2381.
	x	Keaveney et al., "Sequence analysis of the 5' flanking region of the human estrogen receptor gene," <i>DNA sequence-J. DNA Seq. Mapping</i> , 1992; 2:347-358.
	x	Kelly et al., "Rapid action of plasma membrane estrogen receptors," <i>Trends Endocrinol. Metab.</i> , 2001; 12:152-156.
	x	Kermani et al. "Production of ScFv antibody fragments following immunization with a phage-displayed fusion protein and analysis of reactivity to surface-exposed epitopes of the protein F of <i>Pseudomonas aeruginosa</i> by cytofluorometry." 1995 <i>Hybridoma</i> 14:323-328.
	x	Khan et al., "Estrogen receptor expression of benign breast epithelium and its association with breast cancer," <i>Cancer Research</i> , 1994; 54:993-997.
	x	Khoo et al., "Somatic mutations in the BRCA1 gene in the Chinese sporadic breast cancer and ovarian case," <i>Oncogene</i> , 1999; 18:4643-4646.
	x	Klinge "Estrogen receptor interaction with estrogen response elements," <i>Nucleic Acids Research</i> , 2001; 29:2905-2919.
	x	Kohler and Milstein "Continuous cultures of fused cells secreting antibody of predefined specificity." 1975 <i>Nature</i> 256:495-497.
	x	Koleske et al. "Reduction of caveolin and caveolae in oncogenically transformed cells," <i>PNAS</i> , 1995; 92:1381-1385.
	x	Kong et al., "Structure and mechanism of the oestrogen receptor," <i>Biochemical Society Transactions</i> , 2003; 31:56-59.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Kousteni et al. "Reversal of Bone Loss in Mice by non-genotropic signaling of sex steroids." 2002 Science 298:843-846.
	x	Kranenburg et al., "Regulating c-Ras function: cholesterol depletion affects caveolin association, GTP loading, and signaling," <i>Current Biology</i> , 2001; 11:1880-1884.
	x	Kuiper et al. "Cloning of a novel receptor expressed in rat prostate and ovary," <i>PNAS</i> , 1996; 93:5925-5930.
	x	Kurokawa et al., "Inhibition of HER2/ <i>neu</i> ( <i>erbB</i> -2) and mitogen-activated protein kinases enhances Tamoxifen action against HER-2overexpressing, Tamoxifen-resistant breast cancer cells," <i>Cancer Re.</i> , 2000; 60:5887-5894.
	x	Kushner et al., "Construction of cell lines that express high levels of the human estrogen receptor and are killed by estrogens," <i>Molecular Endocrinology</i> , 1990; 4:1465-1473.
	x	Kushner et al., "Estrogen receptor pathway to AP-1," <i>J. Steriod Biochem. Mol. Biol.</i> , 2000; 74:311-317.
	x	Lakhani et al., "The pathology of familial breast cancer: predictive value of Immunohistochemical markers estrogen receptor, progesterone receptor, HER-2 and p53 in patients with mutations in BRCA1 and BRCA2," <i>J. Clin. Oncol.</i> , 2002; 20:2310-2318.
	x	Lam et al., "A New Type of Synthetic Peptide Library for Identifying Ligand-Binding Activity," <i>Nature</i> , 1991; 354:82-84.
	x	Lam, "Mini-Review: An Application of Combinatorial Library Methods in Cancer Research and Drug Discovery," <i>Anti-Cancer Drug Des.</i> , 1997; 12:145-167.
	x	Lannigan, "Estrogen receptor phosphorylation," <i>Steroids</i> , 2003; 68:1-9.
	x	Larrick et al. Methods: A Companion to Methods in Enzymology volume 2 1991; Title page, publisher's page, and p. 106.
	x	Lawson et al., "Low oestrogen receptor a expression in normal human breast tissue underlies low breast cancer incidence in Japan," <i>Lancet</i> , 1999; 351:1787-1788.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Leclercq, "Molecular forms of the estrogen receptor in breast cancer," <i>Journal of Steroid Biochemistry &amp; Molecular Biology</i> , 2002; 80:259-272.
	x	Leclercq et al., "Estrogen Receptor Alpha: Impact of Ligands on Intracellular Shuttling and Turnover Rate in Breast Cancer Cells," <i>Current Cancer Drug Targets</i> , 2006; 6:39-64.
	x	Lee et al., "Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia," <i>American Journal of Pathology</i> , 2002; 161:1357-1369.
	x	Lee et al., "Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells," <i>Oncogene</i> , 1998; 16:1391-1397.
	x	Le Mellay et al., "G $\alpha_{q/11}$ and g $\beta\gamma$ proteins and membrane signaling of calcitriol and estradiol," <i>Journal of Cellular Biochemistry</i> , 1999; 75:138-146.
	x	Levenson et al., "MCF-7: The first hormone-responsive breast cancer cell line," <i>Cancer Research</i> , 1997; 51:3071-3078.
	x	Levin, "Integration of the extranuclear and nuclear actions of estrogen," <i>Molecular Endocrinology</i> , 2005; 19:1951-1959.
	x	Li et al., "Plasma membrane localization and function of the estrogen receptor $\alpha$ variant (ER46) in human endothelial cells," <i>PNAS</i> , 2003; 100:4807-4812.
	x	Liu et al., "Organized endothelial cell surface signal transduction in caveolae distinct from glycosylphosphatidylinositol-anchored protein microdomains," <i>The Journal of Biological Chemistry</i> , 1997; 272:7211-7222.
	x	Liu et al., "Estrogen receptor protects p53 from deactivation by human double minute-2," <i>Cancer Research</i> , 2000; 60:1810-1814.
	x	Liu et al., "Multiple functions of caveolin-1," <i>The Journal of Biological Chemistry</i> , 2002; 277:41295-41298.
	x	Loman et al., "Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes," <i>Cancer (Phila.)</i> , 1998; 83:310-319.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Lonard et al., "The 26S proteasome is required for estrogen receptor $\alpha$ and coactivator turnover and for efficient ER- $\alpha$ transactivation," <i>Mol. Cell</i> , 2000; 5:939-948.
	x	Lonberg et al. "Antigen-specific human antibodies from mice comprising four distinct genetic modifications." 1994 <i>Nature</i> 368:856-859.
	x	Macgregor et al., "Basic guide to the mechanisms of antiestrogen action," <i>Pharmacol. Rev.</i> , 1998; 50:151-196.
	x	Mandlekar et al., "Activation of caspase-3 and cJun NH2-terminal Kinase-1 signaling pathways in tamoxifen-induced apoptosis of human cancer cells," <i>Cancer Research</i> , 2000; 60:5995-6000.
	x	Mandlekar, "Mechanisms of tamoxifen-induced apoptosis," <i>Apoptosis</i> , 2001; 6:469-477.
	x	Maret et al., "Expression of the interleukin-6 gene is constitutive and not regulated by estrogen in rat vascular smooth muscle cells in culture." <i>Endocrinology</i> , 1999; 140:2876.
	x	Margeat et al., "Ligands differentially modulate the protein interactions of the human estrogen receptors alpha and beta." <i>J. Mol. Biol.</i> , 2003; 326:77-92.
	x	Marquez et al., "Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells," <i>Oncogene</i> , 2001; 20:5420-5430.
	x	Marsaud et al., "Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous ER $\alpha$ , differentially affect ER $\alpha$ proteasome-mediated stability, and transcriptional activity in human breast cancer cells," <i>Molecular Endocrinology</i> , 2003; 17:2013-2027.
	x	Mayer and Walker (Eds.) <i>Immuno chemical Methods in Cell and Molecular Biology</i> Academic Press: London, England; 1987. <b>Table of Contents only</b>
	x	McDonnell et al., "Connections and Regulators of the Human Estrogen Receptor." <i>Science</i> , 2002; 296:1642-1644.
	x	McGuire, "Prognostic factors in primary breast cancer," <i>Cancer Surv.</i> 1986; 5:527-536.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	McKay et al., "Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways," <i>Endocr. Rev.</i> , 1999; 20:435-459.
	x	McPherson et al., "Identification of ERF-1 as a member of the AP2 transcription factor family," <i>PNAS</i> , 1997; 94:4342-4347.
	x	Merck Index, Merck Research Laboratories, 13 <sup>th</sup> edition. Whitehouse Station, NJ; 2001; Title page, publisher's page, and table of contents only.
	x	Meienhofer (Li, Ed.) Hormonal Proteins and Peptides volume 2 Academic Press: city, state; 1973. Title page, publisher's page and table of contents only.
	x	Merajver et al., "Germline BRCA1 mutations and loss of the wildtype allele in tumors from families with early-onset breast` and ovarian -cancer," <i>Clin. Cancer Res.</i> , 1995; 1:539-544.
	x	Merrifield, "Synthesis of a Tetrapeptide," <i>J. Am. Chem Soc.</i> , 1963;85:2149-2154.
	x	Migliaccio et al., "Tyrosine kinase/p21 <sup>ras</sup> /MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells," <i>EMBO Journal</i> , 1996; 15:1292-1300.
	x	Miki et al., "A strong candidate for the breast and ovarian-cancer susceptibility gene," <i>Science</i> , 1994; 266:66-71.
	x	Mokbel "Risk-reducing strategies for breast cancer--a review of recent literature," 2003 Int J Fertility and Women's Med. 48(6):274-277.
	x	Mosbys 2004 Drug Guide Mosbys, Inc: St. Louis, MO; 2004. <b>Title page, Table of contents</b>
	x	Narod, "Hormonal prevention of hereditary breast cancer," <i>Ann. NY Acad. Sci.</i> , 2001; 952:36-43.
	x	National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus AL078582, Accession No. AL078582, "Human DNA sequence from clone RP1-13OE4 on chromosome 6q24.2 - 25.3, complete sequence," [online]. Bethesda, MD [retrieved on 2007-06-18]. Retrieved from the Internet: < <a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&amp;id=7161747">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&amp;id=7161747</a> >; 41 pgs.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus AL133564, Accession No. AL133564, "Homo sapiens mRNA; cDNA DKFZp434J186 (from clone DKFZp434J186)," [online]. Bethesda, MD [retrieved on 2006-10-17]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=6599139>; 2 pgs.
	x	National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus AY425004, Accession No. AY425004, "Homo sapiens estrogen receptor 1 (ESR1) gene, complete cds," [online]. Bethesda, MD [retrieved on 2006-10-17]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=37499470>; 131 pgs.
	x	National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus BX640939, Accession No. BX640939, "Homo sapiens mRNA; cDNA DKFZp686N23123 (from clone DKFZp686N23123)," [online]. Bethesda, MD [retrieved on 2006-10-17]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=34365270>; 3 pgs.
	x	National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus HSDJ130E4, Accession No. AL078582, "Human DNA sequence from clone RP1-130E4 on chromosome 6q24.2-25.3 Contains the 3' end of the ESR1 gene for estrogen receptor 1, the 3' end of the synaptic nuclei expressed gene 1b (SYNE-1) (nesprin-1 beta, MYNE1, SYNE1, KIAA0796), complete sequence," [online]. Bethesda, MD [retrieved on 2006-10-17]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=7161747>; 44 pgs.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	



<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus HSM807087, Accession No. BX640939, "Homo sapiens mRNA; cDNA DKFZp686N23123 (from clone DKFZp686N23123)," [online]. Bethesda, MD [retrieved on 2005-03-02]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=34365270>; 3 pgs.
	x	National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus HUMERMCF, Accession No. M12674, "Human estrogen receptor mRNA, complete cds," [online]. Bethesda, MD [retrieved on 2006-10-17]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=182192>; 2 pgs.
	x	National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus NT_004441, Accession No. NT_004441, "Homo sapiens chromosome 1 working draft sequence segment," [online]. Bethesda, MD [retrieved on 2007-06-18]. Retrieved from the Internet: <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucore&id=15296704>; 2 pgs.
	x	National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus XM_048940, Accession No. XM_048940, "Homo sapiens caveolin 1, caveolae protein 22kD (CAV-1), mRNA," [online]. Bethesda, MD [retrieved on 2007-06-18]. Retrieved from the Internet: <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucore&id=14781952>; 2 pgs.
	x	National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenPept Locus AAA52399, Accession No. AAA52399, "estrogen receptor," [online]. Bethesda, MD [retrieved on 2006-10-17]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=182193>; 2 pgs.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenPept Locus CAE45969, Accession No. CAE45969, "hypothetical protein [homo sapiens]," [online]. Bethesda, MD [retrieved on 2004-02-16]. Retrieved from the Internet: < <a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&amp;id=34365271">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&amp;id=34365271</a> >; 2 pgs.
	x	Nawaz et al., "Proteasome-dependent degradation of the human estrogen receptor," <i>Proc. Natl. Acad. Sci. USA</i> , 1999; 96:1858-1862.
	x	Nicholson et al., "Responses to pure antiestrogens (ICI164384, ICI182780) in estrogen-sensitive and-resistant experimental and clinical breast cancer," <i>Ann. NY Acad. Sci.</i> , 1995; 761:148-163.
	x	Nilsson et al., "Mechanisms of estrogen action," <i>Physiological Reviews</i> , 2001; 81:1535-1565.
	x	Nirmala et al., "Ubiquitination of the rat uterine estrogen receptor: dependence on estradiol," <i>Biochem. Biophys. Res. Communi.</i> , 1995; 213:24-31.
	x	Norris et al., "Identification of a third autonomous activation domain within the human estrogen receptor," <i>Mol. Endocrinol.</i> , 1997; 11:747-754.
	x	Obrero et al., "Estrogen receptor-dependent and estrogen receptor-independent pathways for Tamoxifen and 4-hydroxytamoxifen-induced programmed cell death," <i>The Journal of Biological Chemistry</i> , 2002; 277:45695-45703.
	x	Ogawa et al., "Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human," <i>Nucleic Acids Research</i> , 1998; 26:3505-3512.
	x	Okamoto et al., "Caveolins, a family of scaffolding proteins for organizing 'preassembled signaling complexes' at the plasma membrane," <i>The Journal of Biological Chemistry</i> , 1998; 273:5419-5422.
	x	Okuda et al., "Novel splicing events of untranslated first exons in human estrogen receptor $\alpha$ (ER $\alpha$ ) gene," <i>Endocrine Journal</i> , 2003; 50:97-104.
	x	Olson et al., "Production of a biologically active variant form of recombinant human secretin," <i>Peptides</i> 1988; 9:301-307.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Orlandi et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <i>Proc. Nat'l Acad. Sci. USA</i> , 1989; 86:3833-3837.
	x	Osborne et al., "The value of estrogen and progesterone receptors in the treatment of breast cancer," <i>Cancer</i> , 1980; 46(12 Suppl):2884-2888.
	x	Osborne et al., "Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy." <i>Eur. J. Cancer Clin. Oncol.</i> , 1987; 23:1189-1196.
	x	Pack et al. "Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli." 1993 BioTech 11:1271
	x	Page et al., <i>Diagnostic Histopathology of the Breast</i> , Edinburgh, UK, 1987, pages 120-145.
	x	Page et al., "Anatomic markers of human premalignancy and risk of breast cancer," <i>Cancer</i> , 1990; 66:1326-1335.
	x	Petersen et al., "Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue," <i>Cancer Res.</i> , 1987; 47:5748-5751.
	x	Petz et al., "Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site," <i>Mol. Endo.</i> , 2004; 18:521-532.
	x	Physician's Desk Reference 58 <sup>th</sup> Edition Thompson PDR: Des Moines, IA; 2004
	x	Piccart et al., "Evolution Towards Hormone Independence of the MXT Mouse Mammary Tumor is Associated with a Gradual Change in its Estrogen Receptor Molecular Polymorphism," <i>Cancer Biochem Biophys.</i> , 1998; 16:169-182.
	x	Pilat et al., "Characterization of the estrogen receptor transfected MCF10A breast cell line 139B6," <i>Breast Cancer Res. Treat.</i> , 1996; 37:253-266.
	x	Pink et al., "A novel 80kDa human estrogen receptor containing a duplication of exons 6 and 7," <i>Nucleic Acids Research</i> , 1996; 24:962-969.
	x	Pinzone et al., "Molecular and cellular determinants of estrogen receptor $\alpha$ expression," <i>Mol. Cell. Bio.</i> , 2004; 24:4605-4612.

Title page  
and Table  
of contents

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Planas-Silva et al., "Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution," <i>Molecular and Cellular Biology</i> , 1997; 17:4059-4069.
	x	Porter "The hydrolysis of rabbit $\gamma$ -globulin and antibodies with crystalline papain" 1959 <i>Biochem J.</i> 73:119.
	x	Prall et al., "Estrogen Regulation of Cell Cycle Progression in Breast Cancer Cells," <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1998; 65:169-174.
	x	"Polyvinylidene flouride (PVDF)" product datasheet [online]. Millipore Corporation, Billerica, MA, ©1994-2006 Millipore Corporation or an affiliated company. [retrieved on 2006-10-17]. Retrieved from the Internet: <URL:http://www.millipore.com/catalogue.nsf/docs/C3117>; 4 pgs.
	x	Rao et al., "Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts," <i>Oncogene</i> , 1996; 12:523-528.
	x	Razandi et al., "Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ER $\alpha$ and ER $\alpha$ expressed in Chinese hamster ovary cells," <i>Molecular Endocrinology</i> , 1999; 13:307-319.
	x	Razandi et al., "Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer," <i>Molecular Endocrinology</i> , 2000; 14:1434-1447.
	x	Razandi et al., "ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions," <i>Molecular Endocrinology</i> , 2002; 16:100-115.
	x	Razani et al., "Caveolin-1, a putative tumor suppressor gene," <i>Biochemical Society Transactions</i> , 2001; 29:494-499.
	x	Rebbeck et al., "Prophylactic oophorectomy in carriers of BRCA1 OR BRCA2 mutations," <i>N. Engl. J. Med.</i> , 2002; 346:1616-1622.
	x	Reid et al., "Human estrogen receptor- $\alpha$ : regulation by synthesis, modification and degradation," <i>Cellular and Molecular Life Sciences</i> , 2002; 59:821-31.
	x	Reid et al., "Cyclic, proteasome-mediated turnover of unliganded and liganded ER $\alpha$ on responsive promoters is an integral feature of estrogen signaling," <i>Mol. Cell</i> , 2003; 11:695-707.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Riechmann et al., "Reshaping human antibodies for therapy." <i>Nature</i> , 1988; 332:323-327.
	x	Ring et al., "Mechanisms of Tamoxifen resistance," <i>Endocrine-Related Cancer</i> , 2004; 11:643-658.
	x	Robertson "Estrogen receptor downregulators: New antihormonal therapy for advanced breast cancer," 2002 <i>Clinical Therapeutics</i> 24(supp. A): A17-A30.
	x	Rocheftort, "Oestrogen- and anti-estrogen-regulated genes in human breast cancer," <i>Ciba Found Symp.</i> , 1995; 191:254-265.
	x	Rocheftort et al., "Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview," <i>J. Steroid Biochem Mol. Biol.</i> , 1998; 65:163-168.
	x	Rocheftort et al., "How to target estrogen receptor-negative breast cancer?" <i>Endocrine-Related Cancer</i> , 2003; 10:260-266.
	x	Roger et al., "Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors," <i>Hum. Pathol.</i> , 2000; 31:593-600.
	x	Russell et al., "Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling," <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000; 97:5930-5935.
	x	Safe, "Transcriptional Activation of Genes by 17-beta-estradiol Through Estrogen Receptor-Sp1 Interactions." <i>Vitam. Horm.</i> , 2001; 62:231-252.
	x	Sager et al., "RNA genetics of breast cancer: maspin as paradigm," <i>Cold Spring Harb Symp Quant Biol.</i> , 1994; 59:537-546.
	x	Sambrook et al., <i>Molecular Cloning: A Laboratory Manual</i> , 3 <sup>rd</sup> edition, Cold Spring Harbor Press, Cold Spring Harbor, NY, 2001; Title page, publisher's page, and table of contents only.
	x	Sandhu "Protein engineering of antibodies." 1992 <i>Crit Rev. Biotech.</i> 12:437-462.
	x	Sanna et al. "Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries," 1995 <i>PNAS</i> 92:6439

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Santen et al., "The role of mitogen-activated protein (MAP) kinase in breast cancer," <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2002; 80:239-256.
	x	Schlegel et al., "Caveolin-1 potentiates estrogen receptor $\alpha$ (ER $\alpha$ ) signaling, Caveolin-1 drives ligand-independent nuclear translocation and activation of ER $\alpha$ ," <i>J. Biol. Chem.</i> , 1999; 274:33551-33556.
	x	Schlegel et al., "Ligand-independent activation of oestrogen receptor alpha by caveolin-1," <i>Biochem. J.</i> , 1999; 359:203-210.
	x	Schmitz et al. "Phage display: a molecular tool for the generation of antibodies--a review." 2000, <i>Placenta</i> , 21(suppA):S106-112.
	x	Schnitzer et al., "Caveolae from luminal plasmalemma of rat lung endothelium: microdomains enriched in caveolin.Ca2+-ATPase, and inositol triphosphate receptor," <i>PNAS</i> , 1995; 92:1759-1763.
	x	Scott et al., "Searching for peptide ligands with an epitope library," <i>Science</i> , 1990; 249:386-390.
	x	Segars et al., "Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes," <i>Trends in Endocrinology and Metabolism</i> , 2002; 13:349-354.
	x	Shang et al., "Co-factor dynamics and sufficiency in estrogen receptor-regulated transcription," <i>Cell</i> , 2000; 103:843-852.
	x	Shang et al., "Molecular determinants for the tissue specificity of SERMs," <i>Science</i> , 2002; 295:2465-2468.
	x	Shao and Brown "Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy," 2004 <i>Breast Cancer Research</i> 6:39-52.
	x	Sheikh et al., "Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen-receptor-positive breast cancers?" <i>Invasion and Metastasis</i> , 1995; 14:329-336.
	x	Shekhar et al., "Transcriptional activation of functional endogenous estrogen receptor gene expression in MCF10AT cells: a model for early breast cancer," <i>Int. J. Oncol.</i> , 1998; 13:907-15.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Shekhar et al., "Direct action of estrogen on sequence of progression of human preneoplastic breast disease," <i>Am. J. Of Pathl.</i> , 1998; 152:1129-1132.
	x	Shoker et al., "Estrogen receptor-positive proliferating cells in the normal and precancerous breast," <i>American Journal of Pathology</i> , 1999; 155:1811-1815.
	x	Simoncini et al., "Interaction of oestrogen receptor with regulatory subunit of phosphatidylinositol 3-kinase," <i>Nature</i> , 2000; 407:538-541.
	x	Simoncini et al., "Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells," <i>Anterioscier Thromb. Vasc. Biol.</i> , 2003; 193:198-203.
	x	Singer II et al., "Optimal humanization of 1B4 , and anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences." 1993. <i>J. Immunol.</i> , 150:2844-2857.
	x	Smith et al., "Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome," <i>Nature Genet.</i> , 1992; 2:128-131.
	x	Smith et al., "cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype," <i>Oncogene</i> , 1999; 18:6063-6070.
	x	Sommer et al., 2001 "Estrogen Receptor and Breast Cancer." <i>Semin. Cancer Biol.</i> , 11:339-352.
	x	Soule et al., "Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10," <i>Cancer Res.</i> , 1990; 50:6075-6080.
	x	Speir et al., "Competition for p300 Regulates Transcription by Estrogen Receptors and Nuclear Factor-k(beta) in Human Coronary Smooth Muscle Cells." <i>Circ. Res.</i> , 2000; 87:1006-1011.
	x	Stewart et al. Solid Phase Peptide Synthesis W.H. Freeman and Co: San Francisco, CA, 1969. Title page, publisher's page, and table of contents only.
	x	Stoica et al., "Regulation of estrogen receptor- $\alpha$ gene by epidermal growth factor," <i>J. Endocrinol.</i> , 2000; 165:371-378.
	x	Stoner et al., "Hypoxia induces proteasome-dependent degradation of estrogen receptor $\alpha$ in ZR-75-1 breast cancer cells," <i>Mole. Endocrinol.</i> , 2002; 16:2231-2242.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Sui et al., "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells." <i>PNAS</i> , 2002; 99:5515-5520.
	x	Tamrazi et al. "Estrogen Receptor Dimerization: Ligand Binding Regulates Dimer Affinity and Dimer Dissociation Rate." 2002 <i>Mol. Endocrin.</i> 16(12):2706-2719.
	x	Tanimoto et al., "Regulation of estrogen receptor $\alpha$ gene mediated by promoter B responsible for its enhanced expression in human breast cancer," <i>Nucleic Acids Res.</i> , 1999; 27:903-909.
	x	Tatusova et al. 1999 "BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences." <i>FEMS Microbiol. Lett.</i> , 174:247-250.
	x	Taylor et al. "Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM." 1994 <i>Int. Immunol</i> 6:579.
	x	Thompson et al., "CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties, and weight matrix choice." <i>Nucleic Acids Res.</i> , 1994; 22:4673-4680.
	x	Tomlinson et al., "Characterization of a breast cancer cell line derived from a germ line BRCA1 mutation carrier," <i>Cancer Res.</i> , 1998; 58:3237-3242.
	x	Toran-Allerand et al. "ER-X: A novel, plasma-membrane associated, putative estrogen receptor that is regulated during development and after ischemic brain injury." 2002 <i>J. Neuroscience</i> 22:8391-8401.
	x	Toran-Allerand et al. "Minireview: A Plethora of Estrogen Receptors in the Brain: Where Will it End?" 2004 <i>Endocrinology</i> 145(3):1069-1074.
	x	Touitou et al., "Stable transfection of the estrogen receptor cDNA into Hela cells induces estrogen responsiveness of endogenous cathepsin D gene but not of cell growth," <i>Biochemical and Biophysical Research Communications</i> , 1990; 169:109-115.
	x	Tsai et al., "Akt activation by estrogen in estrogen receptor-negative breast cancer cells," <i>Cancer Research</i> , 2001; 61:8390-8392.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	



<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Tsukamoto et al., "Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice." <i>Cell</i> , 1988; 55:619-625.
	x	Turner et al., "Skeletal effects of estrogen." <i>Endocr. Rev.</i> , 1994; 15:275.
	x	Tzukerman et al., "Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions," <i>Molecular Endocrinology</i> , 1994; 8:21-30.
	x	van den Heuvel et al., "Distinct roles for cyclin-dependent kinases in cell cycle control," <i>Science</i> , 1993; 262:2050-2054.
	x	Verhoeven et al. "Reshaping human antibodies: grafting antilysozyme activity." 1988 <i>Science</i> 239:1534
	x	Wang, Zhao-Yi "Estrogen Signaling in Normal and Transformed Cell Growth," Grant Abstract, Grant Number 1R01DK070016-01A2. Available online [retrieved 2006-10-12]. National Institute of Diabetes and Digestive and Kidney Diseases, project dates 2006-04-01 to 2011-03-30. Retrieved from the Internet: <URL:http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?textkey=7104684&p_grant_num=1R01DK070016-01A2&p_query=&ticket=25547686&p_audit_session_id=177068781&p_keywords=>; 2 pgs.
	x	Wang, Zhao-Yi "RB Associated Protein 46 and Breast Cancer Progression," Grant Abstract, Grant Number 5ROI CA84328. Available online [retrieved 2007-05-29]. National Cancer Institute, project dates 2000-07-01 to 2007-06-30. Retrieved from the Internet: <http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?textkey=6795924&p_grant_num=5R01CA084328-05&p_query=&ticket=37767727&p_audit_session_id=243011768&p_keywords=>; 1 pg.
	x	Wang et al., "Identification, cloning, and expression of human estrogen receptor- $\alpha$ 36, a novel variant of human estrogen receptor- $\alpha$ 66," <i>Biochem Biophys Res Commun.</i> , 2005 336(4):1023-7.
	x	Wang et al., "A variant of estrogen receptor- $\alpha$ , hER- $\alpha$ 36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling," <i>PNAS</i> , 2006 Jun 13; 103(24):9063-9068.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Watters et al., "Rapid membrane effects of steroids in neuroblastoma cells: Effects of estrogen on mitogen activated protein kinase signaling cascade and c-fos immediate early gene transcription," <i>Endocrinology</i> , 1997; 138:4030-4033.
	x	Weihua et al., "Update on estrogen signaling." 2003 <i>FEBS Letters</i> 546:17-24.
	x	Weisz et al., "Estrogen regulation of proto-Oncogenes coding for Nuclear Proteins," <i>Critical Reviews in Oncogenesis</i> , 1993; 4:361-388.
	x	Whitlow et al. Methods: A Companion to Methods in Enzymology volume 2 1991 p. 97
	x	Wijayaratne et al., "The human estrogen receptor- $\alpha$ is a ubiquitinated protein whose stability is affected differently by agonists, antagonists and selective estrogen receptor modulators," <i>J. Biol. Chem.</i> , 2001; 276:35684-35692.
	x	Williams et al., "Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice," <i>Molecular Biology of the Cell</i> , 2003; 14:1027-1042.
	x	Wilson et al., "Localization of human BRCA1 and its loss in high grade, non-inherited breast carcinomas," <i>Nature Genet.</i> , 1999; 21:236-240.
	x	Wilson et al. "The use of mRNA display to select high-affinity protein-binding peptides." 2001 <i>PNAS</i> 98:3750.
	x	Yarden et al., "BRCA1 interacts with components of the histone deacetylase complex," <i>Proc. Natl. Acad. Sci. USA</i> , 1999; 96:4983-4988.
	x	Yoshida et al., "Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage," <i>Cancer Sci.</i> , 2004; 95:866-871.
	x	Zhang et al., "Activation of the p38 Mitogen-activated protein kinase pathway by estrogen or 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis," <i>The Journal of Biological Chemistry</i> , 2000; 275:479-468.
	x	Zhang et al., "Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1," <i>The Journal of Biological Chemistry</i> , 2000; 275:20717-20725.

<b>EXAMINER</b>	<b>Date Considered</b>
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> August 30, 2006	<b>Group:</b> 1646
	Information Disclosure Statement mailed: July 9, 2007	

Examiner initial	Copy enclosed	Document Description
	x	Zhang et al., "Inducible Expression of RbAp46 Activates c-Jun NH2-terminal Kinase Dependent Apoptosis and Suppresses Progressive Growth of Tumor Xenografts in Nude Mice," <i>Anticancer Research</i> , 2003; 23:4621-4628.
	x	Zhang et al., "Caveolin-1 Downregulation Activates Estrogen Receptor Alpha Expression and Leads to 17 $\beta$ -estradiol-Stimulated Mammary Tumorigenesis," <i>Anticancer Research</i> , 2005; 25:369-376.
	x	Zheng et al., "BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor," <i>Proc. Natl. Acad. Sci. USA</i> , 2001; 98:9587-9592.
	x	Zhu et al. "Generation and Characterization of Transgenic Mice Expressing Tamoxifen-Inducible Cre-Fusion Protein Specifically in Mouse Liver." 2003 World J. Gastroenterology 9(8):1844-1847.
	x	Zschocke et al., "Estrogen receptor $\alpha$ mediated silencing of caveolin gene expression in neuronal cells," <i>The Journal of Biological Chemistry</i> , 2002; 277:38772-38780.
	x	Zuckermann et al., "Discovery of nanomolar ligands for 7-transmembrane G-protein-coupled receptors from a diverse N-(substituted)glycine peptoid library." <i>J. Med. Chem.</i> , 1994; 37:2678.

<b>EXAMINER</b> /Shulamith Shafer/	<b>Date Considered</b> 09/17/2008
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	